Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interleukin-4
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 29 for your search:
Start Over
Phase I/II Chemoimmunotherapy with IL-2/CY, plus Tumor Infiltrating Lymphocytes in Selected Patients and alpha-Interferon in Some Patients, in Treatment of Advanced Refractory Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: NCI-86-C-183E, NCI-T86-0225N, T86-0225
Phase I/II Study of IL-4 in Patients with Indolent non-Hodgkin's Lymphoma and B-Cell CLL (Summary Last Modified 07/91)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: AECM-9102059, NCI-T91-0050D, T91-0050
Phase I/II Study of TIL/IL-2 in Patients with Advanced Melanoma (Summary Last Modified 12/92)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: PCI-9038, NCI-T91-0133O, T91-0133
Phase II Study of IL-4 for Refractory non-Hodgkin's Lymphoma and Hodgkin's Disease (Summary Last Modified 10/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9219
Phase II Study of IL-4 in Advanced Indolent B-Cell Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: ECOG-E5Y92, E5Y92
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Two Doses of IL-4 for Unresectable Stage IIIA/B non-Small Cell Lung Cancer (Summary Last Modified 04/97)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C94-049, SCH-C94-049-01, NCI-V95-0654
Phase II Randomized Dose-Ranging Study of IL-4 for Advanced Nonsmall Cell Lung Cancer (Summary Last Modified 11/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C94-048, SCH-C94-048-01, NCI-V95-0655
Phase II Study of Interleukin-4 in Patients With Relapsed or Refractory B Lineage Acute Lymphoblastic Leukemia (Summary Last Modified 06/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: NCI
Protocol IDs: SWOG-9711, S9711
Phase II Study of Recombinant Human Interleukin-4 in Patients with Primary Myelofibrosis (Summary Last Modified 06/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: RPCI-DS-95-10, NCI-V97-1360
Phase II Study of Interleukin-4 in Patients with Metastatic Malignant Melanoma (Summary Last Modified 02/91)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: IDB-IL4/MELANOMA, AECM-9003063, CHNMC-COH-9002390031, LUMC-2347, NEMCH-CSU-1919, UCSF-H6042-05366-01, UTHSC-8905011208, NCI-T90-0030O, T90-0030
Phase II Study of Interleukin-4 in Patients with Metastatic or Unresectable Renal Cell Carcinoma (Summary Last Modified 02/91)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: IDB-IL4/RENAL, AECM-9003064, CHNMC-COH-9002290041, LUMC-2348, NEMCH-CSU-1918, UTHSC-8905011209, NCI-T90-0032O, T90-0032
Phase II Study of IL-2 plus TIL with Low-Dose IFN-G in Children with Neuroblastoma Who Have Failed Conventional Chemotherapy (Summary Last Modified 05/92)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 1 to under 21
Sponsor: NCI
Protocol IDs: NCI-90-C-210B, NCI-T90-0110N, T90-0110
Phase II Study of TIL Expanded in Vitro with IL-4/IL-2 and Autologous Tumor Restimulation in Patients with Renal Cell Cancer (Summary Last Modified 12/92)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCF-RPC-3209R, NCI-T92-0172O, T92-0172
Phase II Trial of IL-4 in Patients with Previously Treated Multiple Myeloma (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 15 to 70
Sponsor: NCI
Protocol IDs: UARK-91005, NCI-T91-0115O, T91-0115
Phase II Study of IL-4 in Patients with Previously Untreated CLL and Low-Grade non-Hodgkin's Lymphoma (Summary Last Modified 03/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WSU-C-1041-92, NCI-T92-0167D, T92-0167
Phase II Trial of IL-4 in Patients with Relapsed or Refractory Multiple Myeloma (Summary Last Modified 06/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CWRCC-ICC-1A92, NCI-T92-0161D, T92-0161
Phase II Study of IL-4 for Disseminated or Recurrent Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9230
Phase II Study of IL-4 for Advanced Malignant Melanoma (Summary Last Modified 04/97)
Phase: Phase II
Type: Treatment
Status: Completed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9228
Phase II Study of IL-4 for Previously Treated, Low- or Intermediate-Grade Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-917851, NCCTG-91-78-51
Phase I Study of Subcutaneous IL-4 in Children with Drug-Resistant Acute Leukemia (Summary Last Modified 07/96)
Phase: Phase I
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI
Protocol IDs: SJCRH-IL4, NCI-T94-0101D, T94-0101
Phase I Study of IL-4 in Children with Refractory Leukemia (Summary Last Modified 01/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: NCI
Protocol IDs: POG-9574
Phase I Study of IL-4 Alone or in Combination with IL-2 in Patients with Advanced Cancer (Summary Last Modified 11/90)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI
Protocol IDs: NCI-88-C-141B, NCI-T88-0161N, T88-0161
Phase IA/B Trial of IL-2/IL-4 in Patients with Advanced Malignancies (Summary Last Modified 08/91)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: CCF-RPC-3272C, NCI-B90-0005, B90-0005
Start Over